aTyr Pharma Faces Class Action Lawsuit from Shareholders
The Gross Law Firm has announced the filing of a securities class action on behalf of aTyr Pharma, Inc. (NASDAQ: ATYR) shareholders. This comes as shareholders who purchased shares within a specific class period are encouraged to contact the firm regarding the potential for lead plaintiff appointments. Notably, becoming a lead plaintiff isn’t a requirement for shareholders to participate in recovery.
Class Period and Allegations
The class period spans from November 7, 2024, to September 12, 2025. Allegations within the complaint assert that the defendants made excessively positive statements to investors while also concealing damaging information about the efficacy of Efzofitimod, a treatment option the company has developed. Specifically, it's claimed that they misled investors about the drugs’ effectiveness, specifically its ability to allow patients to reduce their steroid usage completely.
Impact of the Disclosures
The situation took a significant turn on September 15, 2025, when aTyr hosted an investor call revealing that the EFZO-FIT study did not meet its primary goal. During this call, it was disclosed that the study failed to show meaningful change from baseline regarding mean daily doses of the medication after 48 weeks. This unexpected announcement led to the company's stock price plummeting dramatically, falling from a closing price of $6.03 on September 12 to just $1.02 by September 15. This equated to an astonishing drop of 83.2% in just one day.
Deadline for Shareholder Registration
Shareholders are reminded of the crucial deadline of December 8, 2025, by which they must register for this class action. To ensure participation, shareholders are encouraged to submit their information promptly. This is an important step for anyone who acquired shares in aTyr during the specified period.
Next Steps for Interested Shareholders
After registration, shareholders will be enrolled in a portfolio monitoring software designed to keep them updated on the legal proceedings associated with the case. The commitment to being informed is essential as the class action progresses. It's also important to note that there are no fees associated with participation, and no obligation is required to pursue claims as a lead plaintiff.
Why Choose the Gross Law Firm?
The Gross Law Firm stands out as a well-renowned national class action law firm with a mission rooted in protecting the rights of investors. They specialize in cases where deceit, fraud, and unethical business practices have harmed shareholders. Their commitment is to ensure accountability among companies, advocating for shareholders who encounter losses due to misleading statements or material omissions that artificially inflate stock prices. The Gross Law Firm emphasizes that past results do not guarantee similar outcomes but showcases their dedication to justice and recovery for investors.
Contact Information
For more inquiries, shareholders can reach out to The Gross Law Firm directly:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the class action lawsuit about?
The class action lawsuit pertains to allegations that aTyr Pharma misled investors concerning the efficacy of Efzofitimod, impacting stock prices.
Who can participate in the class action?
Shareholders who purchased aTyr shares during the class period from November 7, 2024, to September 12, 2025, can participate.
What is the deadline for registration?
The deadline for shareholders to register for the class action is December 8, 2025.
Why is it important to register?
Registering ensures shareholders receive status updates about the case and can participate in possible recoveries.
What are the costs involved in joining the lawsuit?
There are no fees or obligations associated with participating in this class action lawsuit.
